<DOC>
	<DOCNO>NCT01139320</DOCNO>
	<brief_summary>RATIONALE : Studying sample DNA patient receive gemtuzumab ozogamicin may help doctor learn effect gemtuzumab ozogamicin cell . It may also help doctor understand well patient respond treatment . PURPOSE : This research study study biomarkers DNA sample young patient newly diagnose acute myeloid leukemia receive gemtuzumab ozogamicin .</brief_summary>
	<brief_title>Biomarkers DNA Samples From Younger Patients With Newly Diagnosed Acute Myeloid Leukemia Receiving Gemtuzumab Ozogamicin</brief_title>
	<detailed_description>OBJECTIVES : - To analyze candidate-coding polymorphism CD33 DNA sample child newly diagnose acute myeloid leukemia treat gemtuzumab ozogamicin COG-AAML03P1 . - To determine association polymorphisms clinical response patient treat regimen . OUTLINE : Archived DNA sample analyze candidate polymorphism CD33 PCR-based sequencing .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Gemtuzumab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Newly diagnose acute myeloid leukemia Treated gemtuzumab ozogamicin COGAAML03P1 Genomic DNA sample available PATIENT CHARACTERISTICS : Not specify PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>untreated childhood acute myeloid leukemia myeloid malignancy</keyword>
</DOC>